• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients.

作者信息

Piccolo Vincenzo, Russo Teresa, Nowowiejska Julia, Argenziano Giuseppe, Mazzatenta Carlo, Bassi Andrea

机构信息

Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.

Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland.

出版信息

Dermatol Pract Concept. 2025 Jul 31;15(3):5420. doi: 10.5826/dpc.1503a5420.

DOI:10.5826/dpc.1503a5420
PMID:40790423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12339115/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3215/12339115/b185250c42a2/dp1503a5420g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3215/12339115/b185250c42a2/dp1503a5420g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3215/12339115/b185250c42a2/dp1503a5420g001.jpg

相似文献

1
The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients.度普利尤单抗对儿童特应性皮炎患者生长参数的影响。
Dermatol Pract Concept. 2025 Jul 31;15(3):5420. doi: 10.5826/dpc.1503a5420.
2
The association between expression of CD200 on B lymphocytes and the count of eosinophils and basophils in atopic dermatitis patients with and without dupilumab therapy - Pilot study.B 淋巴细胞表面 CD200 表达与接受和未接受度普利尤单抗治疗的特应性皮炎患者嗜酸性粒细胞和嗜碱性粒细胞计数的相关性 - 初步研究。
Int Immunopharmacol. 2024 May 10;132:112023. doi: 10.1016/j.intimp.2024.112023. Epub 2024 Apr 10.
3
Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.度普利尤单抗对特应性皮炎患者生活质量的影响：一项随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2025 Jun 10;16:1587977. doi: 10.3389/fphar.2025.1587977. eCollection 2025.
4
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
5
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
6
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎：一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
7
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
8
Utility of the Atopic Dermatitis Control Tool for Assessing Long-term Control of Atopic Dermatitis in Korean Patients on Dupilumab.特应性皮炎控制工具在评估接受度普利尤单抗治疗的韩国特应性皮炎患者长期病情控制方面的效用
Allergy Asthma Immunol Res. 2025 Jul;17(4):519-526. doi: 10.4168/aair.2025.17.4.519.
9
Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study.度普利尤单抗治疗特应性皮炎患者的眼表评估：一项前瞻性观察研究。
J Fr Ophtalmol. 2025 Jun;48(6):104544. doi: 10.1016/j.jfo.2025.104544. Epub 2025 May 8.
10
High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis.高剂量度普利尤单抗治疗可快速控制特应性皮炎患儿的疾病。
Front Immunol. 2023 Apr 20;14:1160710. doi: 10.3389/fimmu.2023.1160710. eCollection 2023.

本文引用的文献

1
The effect of atopic dermatitis in pediatric patients on height: Reflections triggered by a real-life case report.特应性皮炎对儿科患者身高的影响：基于真实病例报告引发的思考。
Medicine (Baltimore). 2023 Nov 24;102(47):e36150. doi: 10.1097/MD.0000000000036150.
2
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.一项关于度普利尤单抗治疗6至11岁特应性皮炎儿童有效性和安全性的52周多中心回顾性真实世界研究。
J Dermatolog Treat. 2023 Dec;34(1):2246602. doi: 10.1080/09546634.2023.2246602.
3
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
儿童特应性皮炎患者 6-11 岁接受度普利尤单抗治疗：一项多中心真实世界研究。
Paediatr Drugs. 2022 Nov;24(6):671-678. doi: 10.1007/s40272-022-00531-0. Epub 2022 Aug 27.
4
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗 6 至 11 岁重度特应性皮炎儿童的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床试验。
J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20.